Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 11c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.11 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Strive Enterprises (ASST) Reiterated at Buy by StoneX on Launch of Digital Credit ETF
• Cipher Digital extends Barber Lake lease to 20 years, adding $5.2B revenue
• Abacus Global Management closes $400M life insurance securitization